Potential severe asthma hidden in UK primary care

Funding: ISAR is conducted by Observational & Pragmatic Research Institution (OPRI), and co-funded by OPC Global and AstraZeneca. This research study was co-funded by AstraZeneca and Optimum Patient Care Global Limited, including access to the Optimum Patient Care Research Database (OPCRD).Peer reviewedPublisher PD

Development of the International Severe Asthma Registry (ISAR) : A Modified Delphi Study

This study is cofunded by Optimum Patient Care Global and AstraZeneca.Peer reviewedPostprin

Use of French claims data to investigate burden of disease and unmet needs in asthma and osteoporosis

En France, l'usage des bases de données médico-administratives dans le cadre épidémiologique est récent comparativement à d'autres pays d'Europe, du fait notamment de leur complexité, liée à leur développement initial mené dans une optique comptable. Les travaux menés ont porté sur l'apport de ces bases de données à l'étude de la prise en charge et de la morbidité évitable dans l'asthme et dans l'ostéoporose. Dans un premier temps, nous avons montré que ces bases de données permettaient au travers d'algorithmes d'identifier des nourrissons asthmatiques et leurs exacerbations, et que la prise en charge de ces nourrissons n'était pas optimale en France, avec une forte consommation d'antibiotiques et de corticoïdes oraux. Nous avons prolongé ces recherches par la description de la prise en charge des asthmatiques enfants/adolescents et adultes, et les constats ont été les mêmes. Une surconsommation des traitements de crise a pu être mise en évidence, ainsi que des sous-groupes de patients à risque d'exacerbation sévère. Ces résultats nous ont amené à nous intéresser tout particulièrement à l'adhésion aux traitements de fond. Dans une étude menée sur 5 000 patients asthmatiques, le taux de couverture par un traitement de fond était en moyenne de 51%, et seuls 24% des patients avaient un taux de couverture supérieur ou égal au taux minimal recommandé (80%). Enfin, concernant l'ostéoporose, nous nous sommes attachés à décrire la prise en charge des patients ostéoporotiques sur une période de 6 ans, en nous concentrant particulièrement sur les changements de stratégies thérapeutiquesAnglais In France, the use of claims data in the epidemiological context is recent compared to other European countries, in particular because of their complexity, linked to their initial development for accounting purposes. This work was focused on the contribution of these databases to study disease management and unmet needs in asthma and osteoporosis. First, we showed that it was feasible, through algorithms, to identify in these data infants with asthma and their exacerbations, and we noted that management of these infants was not optimal, with high use of antibiotics and oral corticosteroids. We extended this research by describing the treatment of asthmatic children/adolescents and adults, with similar findings. Overuse of reliever therapy was observed, beyond the identification of subgroups at risk of serious exacerbation. These results led us to focus on adherence to controller therapy. In a study including 5,000 asthma patients, the coverage by controller therapy was 51%, and only 24% of patients had a higher coverage than the recommended minimum (80%). Finally, regarding osteoporosis, we described the treatment of osteoporotic patients over 6 years, with a particular focus on treatment switche

Early adherence to anti-glaucoma therapy: An observational study

International audienceOBJECTIVES: Glaucoma is a major cause of blindness, preventable by a regular therapy. Thus, a good knowledge of patients' adherence to preventive therapy is critical to improve disease management. Early persistence to first-line glaucoma therapy is poorly documented in France. We verified to what extent first-line glaucoma therapy was interrupted within the 12 months following initiation and how this interruption varied with patients' characteristics and drug classes. METHODS: Patients newly-treated with chronic glaucoma therapy (prostaglandins, beta-blockers alone or combined with another therapy, and topical carbonic anhydrase inhibitors) between 2005 and 2008 were identified in the French National Claims data (1/97th random sample). Twelve-month persistence was defined by the presence of the first-line drug class (>=1dispensation) between the 12th and 24th months following initiation. Twelve-month persistence was compared between patients according to the first-line drug classes and baseline characteristics. Proportion of days covered (12 months) and number of quarters with initiated drug class (24 months) were also studied. RESULTS: Among 5331 patients initiated with chronic glaucoma therapy in monotherapy (63% aged >=60 years old, 57% females), initiated therapy mainly consisted of prostaglandins (43%) and beta-blockers alone (32%). Only 45% of the patients were persistent to first-line therapy 12 months after initiation. Salient differences in persistence rates appeared between drug classes (P\\textless0.0001): from 59% with prostaglandins to 26% for topical carbonic anhydrase inhibitors. Better results also appeared for prostaglandins with other dimensions of adherence. Non-persistent patients were more likely younger than 40, or conversely aged>=80 (P\\textless0.0001). They were also more likely to necessitate social assistance for therapy (P=0.0007). No salient difference appeared as to gender. CONCLUSIONS: Our findings confirm the low early persistence of first-line therapy, despite better results for prostaglandins. Education of patients and identification of barriers to adherence could contribute to improve quality of care

Trajectories of Controller Therapy Use Before and After Asthma-Related Hospitalization in Children and Adults: Population-Based Retrospective Cohort Study

BackgroundInappropriate use of inhaled corticosteroids (ICSs) for asthma impairs control and may cause exacerbation, including asthma-related hospitalization (ARH). In prospective studies, ICS use peaked around ARH, but information on routine care use is limited. Since ARH is a major outcome, controller therapy use in routine care before and after ARH should be documented. ObjectiveThis study aimed to distinguish ICS use typologies (trajectories) before and after ARH, and assess their relationships with sociodemographic, disease, and health care characteristics. MethodsA retrospective cohort study was performed using a 1% random sample of the French claims database. All patients hospitalized for asthma between January 01, 2013, and December 31, 2015, were classified as either children (aged 1-10 years) or teens/adults (aged ≥11 years). Health care resource use was assessed between 24 and 12 months before ARH. ICS use was computed with the Continuous Measures of Medication Acquisition-7 (CMA7) for the 4 quarters before and after ARH. Initially, the overall impact of hospitalization on the CMA7 value was studied using a segmented regression analysis in both children and teens/adults. Then, group-based trajectory modeling differentiated the groups with similar ICS use. We tested different models having 2 to 5 distinct trajectory groups before selecting the most appropriate trajectory form. We finally selected the model with the lowest Bayesian Information Criterion, the highest proportion of patients in each group, and the maximum estimated probability of assignment to a specific group. ResultsOverall, 863 patients were included in the final study cohort, of which 447 (51.8%) were children and 416 (48.2%) were teens/adults. In children, the average CMA7 value was 12.6% at the start of the observation period, and there was no significant quarter-to-quarter change in the value (P=.14) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 34.9% (P=.001), before a significant decrease (P=.01) of 7.0% per quarter. In teens/adults, the average CMA7 value was 31.0% at the start, and there was no significant quarter-to-quarter change in the value (P=.08) before hospitalization. Immediately after hospitalization, the average CMA7 value rose by 26.9% (P=.002), before a significant decrease (P=.01) of 7.0% per quarter. We identified 3 and 5 trajectories before ARH in children and adults, respectively, and 5 after ARH for both groups. Trajectories were related to sociodemographic characteristics (particularly, markers of social deprivation) and to potentially inappropriate health care, such as medical management and choice of therapy. ConclusionsAlthough ARH had an overall positive impact on ICS use trajectories, the effect was often transient, and patient behaviors were heterogeneous. Along with overall trends, distinct trajectories were identified, which were related to specific patients and health care characteristics. Our data reinforce the evidence that inappropriate use of ICS paves the way for ARH

Long-Term Inhaled Corticosteroid Adherence in Asthma Patients with Short-Term Adherence

International audienceBACKGROUND: Although the use of inhaled corticosteroids (ICS) in asthma is known to be overall erratic, the long-term use of ICS by patients selected during an episode of regular use is poorly documented. OBJECTIVE: In a cohort of patients with asthma regularly acquiring ICS therapy over several months, we verified whether these patients remained treated in the following 12 months. The correlates of regular ICS use over this period were investigated. METHODS: A historical cohort of patients with asthma was identified from the Echantillon généraliste de bénéficiaires national French health care reimbursement data (2007-2012). Patients (6-40 years) were selected during a regular ICS use episode, with 3 or more ICS refills within 120 days. Continuous multiple-interval measures of medication availability (CMA) were computed for the 12 months after the third dispensation, and the factors associated with a CMA value of 80% or more (adherent patients) were identified. RESULTS: Among 5096 patients (42.1% children/teenagers, 48.8% females), only 24.0% had a CMA value of 80% or more (mean CMA = 54.4%) over the 12 months following the ICS selection period. Achieving a CMA value of 80% or more was primarily associated with being a child/teenager (P = .002), having more severe or less controlled asthma (P = .007), more previous dispensing of short-acting beta agonists (P \\textless .0001), and receiving devices with 200 unit doses (P \\textless .0001). Adherent patients had more frequent general practitioner visits (P \\textless .0001), more distinct prescribers of respiratory therapy (P = .0002), and more frequent switches of ICS (P \\textless .0001). CONCLUSIONS: Most patients with asthma selected during an episode of regular ICS use did not maintain therapy over the following months. Adherence should be repeatedly monitored, and the reasons for discontinuation should be investigated, at prescriber and patient levels

Relative exposure to controller therapy and asthma exacerbations: a validation study in community pharmacies

International audiencePURPOSE: "Controllers-to-total asthma drug" ratios computed from claims data identify asthmatics at risk of exacerbations. Direct link of ratios to data obtained from patients, such as control and recent outcomes, would facilitate their interpretation. We studied the relationship between R1 ratio (inhaled corticosteroids (ICS)/total anti-asthma drug ratio) and the Asthma Control Test. Comparisons were also conducted for secondary outcomes (asthma-related hospital contacts, monthly medical contacts, use of oral corticosteroids, and perception of disease burden). Results with R1 ratio were compared with those obtained with a second ratio, "ICS-plus-leukotriene receptor antagonist/total asthma drug" (R2 = ICS + leukotriene receptor antagonist/total anti-asthma drugs). METHODS: A survey was conducted in community pharmacies. Patients visiting with a prescription of anti-asthma drug and >=12 months of drug dispensing recorded in the pharmacy were consecutively recruited. Dispensing data were linked to patient-reported outcomes. Asthma control and secondary outcomes were compared for both ratios between low-controller-ratio (R \\textless 50%) and high-controller-ratio groups (R >= 50%), after excluding null values. RESULTS: Of the 919 eligible patients (mean age 37 years, 55% women), 90.2% and 92.4% had non-null values for R1 and R2, respectively. Compared with the low-controller-ratio groups, adjusted risks of being uncontrolled were significantly lower in the high-controller-ratio groups (RR = 0.64, 95%CI [0.54, 0.77] and RR = 0.57, 95%CI [0.47, 0.70], for R1 and R2 ratios, respectively). Likewise, fewer patients with secondary outcomes were observed in the high-controller-ratio groups, for both ratios. CONCLUSION: Asthma was better controlled among patients with high controller ratios, along with fewer asthma-related outcomes, for both R1 and R2 ratios. This confirms the utility of asthma/drug ratios in identifying patients at risk of exacerbations, notably in claims data. Copyright \textcopyright 2014 John Wiley & Sons, Ltd